A Study Of Lorlatinib Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC
Clinical trial NCT03052608 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT03052608
- Sponsor
- Pfizer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2017-04-27
- Primary completion
- 2020-03-20
- Enrollment
- 296
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.